Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New schedule for tobramycin administration

R D Lawson, G P Bodey, T Pan

    Antimicrobial Agents and Chemotherapy
    |May 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Serious complications of vascular catheter-related Staphylococcus aureus bacteremia in cancer patients.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·1992
    Same author

    Infectious complications of indwelling vascular catheters.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same author

    Viral pneumonia in the immunocompromised adult with neoplastic disease: the role of common community respiratory viruses.

    Seminars in respiratory infections·1992
    Same author

    Lack of activity of amphotericin B in systemic murine fusarial infection.

    The Journal of infectious diseases·1992
    Same author

    Evaluation of strategies for central venous catheter replacement.

    Critical care medicine·1992
    Same author

    Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1992
    Same journal

    Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    An Achilles' heel for methicillin-resistant <i>Staphylococcus aureus</i>? Re-evaluating β-lactam susceptibility of MRSA.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Essential role of glycogen synthase kinase 3 in regulating growth, drug response, and infectivity in <i>Leishmania infantum</i>.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    <i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

    Antimicrobial agents and chemotherapy·2026
    Same journal

    Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

    Antimicrobial agents and chemotherapy·2026
    See all related articles

    This study evaluated a tobramycin dosing schedule. While effective for many, it caused significant serum concentration fluctuations, with some patients experiencing levels too low or too high.

    Area of Science:

    • Pharmacology
    • Clinical Pharmacy
    • Infectious Diseases

    Background:

    • Tobramycin is an aminoglycoside antibiotic used for serious infections.
    • Optimizing tobramycin dosing is crucial to balance efficacy and minimize toxicity.
    • Intermittent dosing schedules can lead to variable serum concentrations.

    Purpose of the Study:

    • To assess the pharmacokinetic profile of a specific tobramycin dosing regimen.
    • To evaluate the safety and efficacy of this regimen in a larger patient cohort.
    • To identify potential issues with serum concentration variability.

    Main Methods:

    • Ten patients received an initial loading dose followed by intermittent infusions every 4 hours.
    • Serum tobramycin concentrations were measured at various time points.

    Related Experiment Videos

  • The regimen was subsequently used to treat 117 patients with infections.

    • Main Results:

    • Peak serum tobramycin concentrations averaged 6.0 µg/ml after the loading dose.
    • Trough concentrations averaged 3.0 µg/ml two hours post-infusion.
    • Only 60% of patients achieved target therapeutic serum levels (3-10 µg/ml).

    Conclusions:

    • The evaluated intermittent tobramycin schedule results in significant serum concentration fluctuations.
    • This dosing regimen may lead to subtherapeutic troughs or excessively high peaks in some patients.
    • Further optimization of tobramycin administration protocols is warranted.